Cancer Center Amsterdam

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Vergote, I., Gonzalez-Martin, A., Fujiwara, K., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F. C., Lorusso, D., Yonemori, K., van Nieuwenhuysen, E., Manso, L., Woelber, L., Westermann, A., Covens, A., Hasegawa, K., Kim, B-G., Raimondo, M., Bjurberg, M., & 11 othersCruz, F. M., Angelergues, A., Cibula, D., Barraclough, L., Oaknin, A., Gennigens, C., Nicacio, L., Teng, M. S. L., Whalley, E., Soumaoro, I. & InnovaTV 301/ENGOT-cx12/GOG-3057 Collaborators, 4 Jul 2024, In: New England journal of medicine. 391, 1, p. 44-55 12 p.

Research output: Contribution to journal › Article › Academic › peer-review

Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol

van der Ploeg, P., Hendrikse, C. S. E., Thijs, A. M. J., Westgeest, H. M., Smedts, H. P. M., Vos, M. C., Jalving, M., Lok, C. A. R., Boere, I. A., van Ham, M. A. PC., Ottevanger, P. B., Westermann, A. M., Mom, C. H., Lalisang, R. I., Lambrechts, S., Bekkers, R. L. M. & Piek, J. M. J., 15 Jan 2024, In: Heliyon. 10, 1, e23170.

Research output: Contribution to journal › Article › Academic › peer-review

PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer

Westermann, A., Ottevanger, P., Reyners, A., Kroep, J. R., van Oijen, M. G. H., Lalisang, R. & Witteveen, P. O., 2024, (E-pub ahead of print) In: International journal of gynecological cancer. ijgc-2023-004781.

Research output: Contribution to journal › Article › Academic › peer-review